SCHEMBL22645341

SCHEMBL22645341

CCCNC(=O)/C(=C/c1ccccc1)NC(=O)/C=C/c1ccccc1

nearest known ligand 0.59

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.59
NPSR1 Q6W5P4 1/20 0.59
EGFR P00533 3/20 0.56
KMT2A Q03164 1/20 0.52
HDAC3 O15379 3/20 0.52
MMP1 P03956 2/20 0.49
MMP2 P08253 2/20 0.49
MMP9 P14780 2/20 0.49
RECQL P46063 2/20 0.49
SMN1; SMN2 Q16637 2/20 0.49
LMNA P02545 1/20 0.49
POLB P06746 1/20 0.49
HDAC1 Q13547 2/20 0.48
HDAC2 Q92769 2/20 0.48
NCOR2 Q9Y618 1/20 0.48
HTT P42858 1/20 0.48
HDAC4 P56524 1/20 0.47
HDAC8 Q9BY41 1/20 0.47
HDAC6 Q9UBN7 1/20 0.47
RAB9A P51151 2/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22645524 0.94 ALDH1A1 (0.54) ALDH1A1NPSR1EGFRKMT2AHDAC3
SCHEMBL22662495 0.93 ALDH1A1 (0.53) ALDH1A1NPSR1EGFRKMT2AHDAC3
SCHEMBL22645393 0.93 ALDH1A1 (0.53) ALDH1A1NPSR1EGFRKMT2AHDAC3
SCHEMBL22645390 0.93 ALDH1A1 (0.53) ALDH1A1NPSR1EGFRKMT2AHDAC3
SCHEMBL22645552 0.93 MAPT (0.53) ALDH1A1NPSR1EGFRKMT2AHDAC3
SCHEMBL22645300 0.92 EGFR (0.64) ALDH1A1NPSR1EGFRKMT2AHDAC3
SCHEMBL22645382 0.91 ALDH1A1 (0.51) ALDH1A1NPSR1EGFRKMT2AHDAC3
SCHEMBL22645443 0.91 KMT2A (0.57) ALDH1A1NPSR1EGFRKMT2AHDAC3
SCHEMBL22662493 0.91 ALDH1A1 (0.51) ALDH1A1NPSR1EGFRKMT2AHDAC3
SCHEMBL22645383 0.91 ALDH1A1 (0.51) ALDH1A1NPSR1EGFRKMT2AHDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11312694-B2 Method for making propenamide compound KING ABDULAZIZ UNIVERSITY (SA) 2022-04-26 US disclosed
US-11312694-B2 Method for making propenamide compound KING ABDULAZIZ UNIVERSITY (SA) 2022-04-26 US disclosed
US-20220033368-A1 METHOD FOR MAKING PROPENAMIDE COMPOUND KING ABDULAZIZ UNIVERSITY (SA) 2022-02-03 US disclosed
US-20220033368-A1 METHOD FOR MAKING PROPENAMIDE COMPOUND KING ABDULAZIZ UNIVERSITY (SA) 2022-02-03 US disclosed
US-20220009896-A1 METHOD OF TREATING COLORECTAL CANCER KING ABDULAZIZ UNIVERSITY (SA) 2022-01-13 US disclosed
US-20220009896-A1 METHOD OF TREATING COLORECTAL CANCER KING ABDULAZIZ UNIVERSITY (SA) 2022-01-13 US disclosed
US-11214556-B1 Method of treating colorectal cancer KING ABDULAZIZ UNIVERSITY (SA) 2022-01-04 US disclosed
US-11214556-B1 Method of treating colorectal cancer KING ABDULAZIZ UNIVERSITY (SA) 2022-01-04 US disclosed
US-11155528-B2 Bis-propenamide compounds and methods of treating cancer KING ABDULAZIZ UNIVERSITY (SA) 2021-10-26 US disclosed
US-11155528-B2 Bis-propenamide compounds and methods of treating cancer KING ABDULAZIZ UNIVERSITY (SA) 2021-10-26 US disclosed
US-20210122721-A1 BIS-PROPENAMIDE COMPOUNDS AND METHODS OF TREATING CANCER KING ABDULAZIZ UNIVERSITY (SA) 2021-04-29 US disclosed
US-20210122721-A1 BIS-PROPENAMIDE COMPOUNDS AND METHODS OF TREATING CANCER KING ABDULAZIZ UNIVERSITY (SA) 2021-04-29 US disclosed
US-10836736-B1 Pharmaceutical composition with cytotoxic activity on colorectal cancer cells KING ABDULAZIZ UNIVERSITY (SA) 2020-11-17 US disclosed
US-10836736-B1 Pharmaceutical composition with cytotoxic activity on colorectal cancer cells KING ABDULAZIZ UNIVERSITY (SA) 2020-11-17 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10836736-B1 Pharmaceutical composition with cytotoxic activity on colorectal cancer cells APC, DCK, ABCB1 ALDH1A1 695/4885NPSR1 3962/4885EGFR 144/4885
US-20210122721-A1 BIS-PROPENAMIDE COMPOUNDS AND METHODS OF TREATING CANCER APC, CCNE1, CCNI ALDH1A1 392/4885NPSR1 1871/4885EGFR 78/4885
US-20220009896-A1 METHOD OF TREATING COLORECTAL CANCER APC, SLC10A2, FOLR1 ALDH1A1 350/4885NPSR1 3434/4885EGFR 107/4885
US-11312694-B2 Method for making propenamide compound APC, CYP2C19, PKD1 ALDH1A1 353/4885NPSR1 1752/4885EGFR 137/4885
US-20220033368-A1 METHOD FOR MAKING PROPENAMIDE COMPOUND APC, CYP2C19, PKD1 ALDH1A1 353/4885NPSR1 1752/4885EGFR 137/4885
US-11155528-B2 Bis-propenamide compounds and methods of treating cancer APC, CCNE1, CCNI ALDH1A1 392/4885NPSR1 1871/4885EGFR 78/4885
US-11214556-B1 Method of treating colorectal cancer APC, SLC10A2, FOLR1 ALDH1A1 350/4885NPSR1 3434/4885EGFR 107/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.